Phase IV study of afatinibas second-line therapy for patients with locally advanced ormetastatic NSCLC harboringcommon EGFR mutations | boehringer-ingelheim.pt

DOWNLOAD PDF (825.62 KB)

Phase IV study of afatinibas second-line therapy for patients with locally advanced ormetastatic NSCLC harboringcommon EGFR mutations

Transferir o PDFof Phase IV study of afatinibas second-line therapy for patients with locally advanced ormetastatic NSCLC harboringcommon EGFR mutations